Back to mobile site

Truist Reiterates Buy Rating on Axsome Therapeutics (AXSM)

January 2, 2026 8:53 AM EST Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $200.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login